Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel W. Zaharevitz is active.

Publication


Featured researches published by Daniel W. Zaharevitz.


British Journal of Cancer | 2001

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

Josie I Johnson; Sebastian Decker; Daniel W. Zaharevitz; Lawrence Rubinstein; John M. Venditti; S A Schepartz; Sivaram Kalyandrug; Michaele C. Christian; Susan F. Arbuck; Melinda G. Hollingshead; Edward A. Sausville

An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institutes Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10–7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10–4 M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity.


Radiation Research | 2004

Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003

Helen B. Stone; John E. Moulder; C. Norman Coleman; K. Kian Ang; Mitchell S. Anscher; Mary Helen Barcellos-Hoff; William S. Dynan; John R. Fike; David J. Grdina; Joel S. Greenberger; Martin Hauer-Jensen; Richard P. Hill; Richard Kolesnick; Thomas J. MacVittie; Cheryl Marks; William H. McBride; Noelle F. Metting; Terry C. Pellmar; Mary Purucker; Mike E. Robbins; Robert H. Schiestl; Thomas M. Seed; Joseph E. Tomaszewski; Elizabeth L. Travis; Paul E. Wallner; Mary Wolpert; Daniel W. Zaharevitz

Abstract Stone, H. B., Moulder, J. E., Coleman, C. N., Ang, K. K., Anscher, M. S., Barcellos-Hoff, M. H., Dynan, W. S., Fike, J. R., Grdina, D. J., Greenberger, J. S., Hauer-Jensen, M., Hill, R. P., Kolesnick, R. N., MacVittie, T. J., Marks, C., McBride, W. H., Metting, N., Pellmar, T., Purucker, M., Robbins, M. E., Schiestl, R. H., Seed, T. M., Tomaszewski, J., Travis, E. L., Wallner, P. E., Wolpert, M. and Zaharevitz, D. Models for Evaluating Agents Intended for the Prophylaxis, Mitigation and Treatment of Radiation Injuries. Report of an NCI Workshop, December 3–4, 2003. Radiat. Res. 162, 711–728 (2004). To develop approaches to prophylaxis/protection, mitigation and treatment of radiation injuries, appropriate models are needed that integrate the complex events that occur in the radiation-exposed organism. While the spectrum of agents in clinical use or preclinical development is limited, new research findings promise improvements in survival after whole-body irradiation and reductions in the risk of adverse effects of radiotherapy. Approaches include agents that act on the initial radiochemical events, agents that prevent or reduce progression of radiation damage, and agents that facilitate recovery from radiation injuries. While the mechanisms of action for most of the agents with known efficacy are yet to be fully determined, many seem to be operating at the tissue, organ or whole animal level as well as the cellular level. Thus research on prophylaxis/protection, mitigation and treatment of radiation injuries will require studies in whole animal models. Discovery, development and delivery of effective radiation modulators will also require collaboration among researchers in diverse fields such as radiation biology, inflammation, physiology, toxicology, immunology, tissue injury, drug development and radiation oncology. Additional investment in training more scientists in radiation biology and in the research portfolio addressing radiological and nuclear terrorism would benefit the general population in case of a radiological terrorism event or a large-scale accidental event as well as benefit patients treated with radiation.


Nature Structural & Molecular Biology | 2004

Identification of small molecule inhibitors of anthrax lethal factor

Rekha G. Panchal; Ann R. Hermone; Tam Luong Nguyen; Thiang Yian Wong; Robert Schwarzenbacher; James J. Schmidt; Douglas Lane; Connor F. McGrath; Benjamin E. Turk; James C. Burnett; M. Javad Aman; Stephen F. Little; Edward A. Sausville; Daniel W. Zaharevitz; Lewis C. Cantley; Robert C. Liddington; Rick Gussio; Sina Bavari

The virulent spore-forming bacterium Bacillus anthracis secretes anthrax toxin composed of protective antigen (PA), lethal factor (LF) and edema factor (EF). LF is a Zn-dependent metalloprotease that inactivates key signaling molecules, such as mitogen-activated protein kinase kinases (MAPKK), to ultimately cause cell death. We report here the identification of small molecule (nonpeptidic) inhibitors of LF. Using a two-stage screening assay, we determined the LF inhibitory properties of 19 compounds. Here, we describe six inhibitors on the basis of a pharmacophoric relationship determined using X-ray crystallographic data, molecular docking studies and three-dimensional (3D) database mining from the US National Cancer Institute (NCI) chemical repository. Three of these compounds have Ki values in the 0.5–5 μM range and show competitive inhibition. These molecular scaffolds may be used to develop therapeutically viable inhibitors of LF.


Pharmacology & Therapeutics | 1999

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.

Edward A. Sausville; Daniel W. Zaharevitz; Robert Gussio; Laurent Meijer; Maryse Louarn-Leost; Conrad Kunick; Robert Schultz; Tyler Lahusen; Donna Headlee; Sherman F. Stinson; Susan G. Arbuck; Adrian M. Senderowicz

Cyclin-dependent kinases (CDKs) have been recognized as key regulators of cell cycle progression. Alteration and deregulation of CDK activity are pathogenic hallmarks of neoplasia. Therefore, inhibitors or modulators would be of interest to explore as novel therapeutic agents in cancer, as well as other hyperproliferative disorders. Flavopiridol is a semisynthetic flavonoid that emerged from an empirical screening program as a potent antiproliferative agent that mechanistic studies demonstrated to directly inhibit CDKs 1, 2, and 4 as a competitive ATP site antagonist. Initial clinical trials have shown that concentrations that inhibit cell proliferation and CDK activity in vitro can be safely achieved in humans, and additional clinical trials will establish its clinical potential. To address the need for additional chemotypes that may serve as lead structures for drugs that would not have the toxicities associated with flavopiridol, compounds with a similar pattern of cell growth inhibitory activity in the National Cancer Institutes in vitro anticancer drug screen have been recognized by the computer-assisted pattern recognition algorithm COMPARE and then screened for anti-CDK activity in a biochemical screen. The benzodiazepine derivative NSC 664704 (7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one) was revealed by that approach as a moderately potent (IC50 0.4 microM) inhibitor of CDK2, which in initial experiments shows evidence of causing cell cycle redistribution in living cells. NSC 664704 is, therefore, a candidate for further structural optimization, guided in part by understanding of the ATP-binding site in CDK2. This approach represents one way of combining empirical screening information with structure-based design to derive novel candidate therapeutic agents directed against an important cellular target.


Journal of Chemical Information and Computer Sciences | 1994

National Cancer Institute Drug Information System 3D database

George W. A. Milne; Marc C. Nicklaus; John S. Driscoll; Shaomeng Wang; Daniel W. Zaharevitz

A searcheable database of three-dimensional structures has been developed from the chemistry database of the NCI Drug Information System (DIS), a file of about 450,000 primarily organic compounds which have been tested by NCI for anticancer activity. The DIS database is very similar in size and content to the proprietary databases used in the pharmaceutical industry; its development began in the 1950s; and this history led to a number of problems in the generation of 3D structures.


Chemistry & Biology | 2000

Chemical synthesis and biological properties of pyridine epothilones

K. C. Nicolaou; Rita Scarpelli; Birgit Bollbuck; Barbara Werschkun; Pereira Mm; Markus Wartmann; Karl-Heinz Altmann; Daniel W. Zaharevitz; Rick Gussio; Paraskevi Giannakakou

BACKGROUND Numerous analogs of the antitumor agents epothilones A and B have been synthesized in search of better pharmacological profiles. Insights into the structure-activity relationships within the epothilone family are still needed and more potent and selective analogs of these compounds are in demand, both as biological tools and as chemotherapeutic agents, especially against drug-resistant tumors. RESULTS A series of pyridine epothilone B analogs were designed, synthesized and screened. The synthesized compounds exhibited varying degrees of tubulin polymerization and cytotoxicity properties against a number of human cancer cell lines depending on the location of the nitrogen atom and the methyl substituent within the pyridine nucleus. CONCLUSIONS The biological screening results in this study established the importance of the nitrogen atom at the ortho position as well as the beneficial effect of a methyl substituent at the 4- or 5-position of the pyridine ring. Two pyridine epothilone B analogs (i.e. compounds 3 and 4) possessing higher potencies against drug-resistant tumor cells than epothilone B, the most powerful of the naturally occurring epothilones, were identified.


Annals of the New York Academy of Sciences | 2006

Inhibition of CDKs as a Therapeutic Modality

Edward A. Sausville; Jill Johnson; Michael C. Alley; Daniel W. Zaharevitz; Adrian M. Senderowicz

Abstract: Altered cell cycle control has emerged as a recurring theme in neoplasia. Strategies that would return toward normal the altered cell cycle control present in tumor cells have appeal as novel approaches to cancer treatment. Cyclin‐dependent kinases (CDKs) control the progression through the cell cycle, operating at the transition from the G2 to M and G1 to S phases, and progression through S. CDKs are regulated by a complex set of mechanisms, including the presence of activating cyclins, regulatory phosphorylations, and endogenous CDK inhibitors at “checkpoints.” This overview focuses on progress in defining compounds that can antagonize directly the action of CDKs. These have emerged as various types of ATP site‐directed inhibitors, including flavopiridol, N‐substituted adenine derivatives, the natural product butyrolactone, staurosporine derivatives, and, more recently, the synthetic paullones. Paullones appear to be of interest in that one of the most active members of the class, 9‐nitropaullone (alsterpaullone), requires relatively brief periods of exposure to living cells in order to effect lasting effects on cellular and proliferative potential. Two of these compounds, flavopiridol and UCN‐01 (7‐hydroxy‐staurosporine), have entered early clinical trials and achieved concentrations that might potentially modulate CDK function. In the case of UCN‐01, unexpected human plasma protein binding might prevent direct inhibition of CDKs but allow drug concentrations to be achieved that indirectly affect CDKs by checkpoint abrogation. Further studies with CDK inhibitors should define the expected end point of CDK inhibition more clearly in preclinical models and clinical systems, including cytostasis, apoptosis, or differentiation.


Archives of Biochemistry and Biophysics | 1981

Membrane effects of retinoids: Possible correlation with toxicity

Robert G. Meeks; Daniel W. Zaharevitz; Raymond F. Chen

Abstract The mechanism of toxicity of vitamin A and other retinoids is unknown. One theory holds that these compounds disrupt cellular function by acting on membranes as detergents would. Using rat erythrocyte ghosts labeled with fluorescent probes, we studied the changes in fluorescence polarization effected by detergents and retinoids. Fluorescence lifetime measurements allowed us to calculate apparent microviscosities. Sodium dodecyl sulfate, Triton X-100, and lysophosphatidylcholine seemed to cause a structural transition in the membrane where the apparent microviscosity was reduced by half at a detergent concentration of approximately 10−3 m ; the same transition point was reported by 1,6-diphenylhexatriene or perylene. In contrast, retinoic acid reduced membrane microviscosity by half at a concentration of only 10−5 m or lower. Furthermore, the results obtained with DPH were very different from those obtained with perylene as the probe. The effect of retinoic acid was prevented by d-α-tocopherol acetate. Other retinoids were also effective in reducing membrane microviscosity, and the order of their effectiveness exactly paralleled the order of their toxicities, as determined by others using bioassays. These results suggest that retinoid toxicity may indeed be related to a membrane effect, but the action of retinoids on membranes is unlike that of simple detergents.


Biochemical Pharmacology | 1981

Dose-dependent kinetics of all-trams-retinoic acid in rats: Plasma levels and excretion into bile, urine, and faeces

Brian N. Swanson; Charles A. Frolik; Daniel W. Zaharevitz; Peter P. Roller; Michael B. Sporn

Abstract Plasma concentration-time curves for all-trans-retinoic acid (RA) after 0.015.0.25 or 5 mg/kg, i.V., deviated from first-order kinetics in the rat. Within 10 min after the i.v. infusion, a rapid, dose-dependent decrease in RA concentration was observed (slope steepest at the lowest dose). During a secondary phase of slower decline, the times required to halve the RA concentration after 0.015, 0.25 and 5 mg/kg were 40, 65 and 120 min respectively. At later times, the concentration-time curves for all three dose levels assumed a fast rate of decline (half-life about 19 min at the lower dose). The dose-dependent kinetics of RA in plasma were not due to enterohepatic recirculation of RA, since RA levels in plasma were not lower in rats with biliary fistulas given comparable doses. In contrast, circulating levels of RA metabolites remained elevated for several hours and were significantly diminished by interruption of the enterohepatic circulation. After a dose of [10-3H]RA, the rate of biliary excretion of radiolabeled material was initially slower after 5 mg/kg RA than after 0.015 mg/kg RA. Within the first 24 hr, however, approximately the same proportion of both doses appeared in bile. All-trans-retinoyl-β-glucuronide is only a minor biliary metabolite of RA. Glucuronidation of RA was dose-dependent, since the percentage of total biliary metabolites represented by all-trans-retinoyl-β-glucuronide increased with increasing dose. Renal excretion of RA and its metabolites was significantly decreased by interruption of the enterohepatic circulation. The percentage of dose excreted in the urine decreased with increasing dose.


Bioorganic & Medicinal Chemistry Letters | 2000

2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity

Conrad Kunick; Christiane Schultz; Thomas Lemcke; Daniel W. Zaharevitz; Rick Gussio; Ravi K. Jalluri; Edward A. Sausville; Maryse Leost; Laurent Meijer

9-Trifluoromethyl-paullones with a carbon chain in the 2-position were synthesized by palladium-catalyzed coupling reactions of a 2-iodoprecursor with terminal alkenes or alkynes, respectively. The introduction of a 2-cyanoethyl substituent led to a significant enhancement of CDK1/cyclin B inhibiting property and in vitro antiproliferative activity.

Collaboration


Dive into the Daniel W. Zaharevitz's collaboration.

Top Co-Authors

Avatar

Rick Gussio

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Conrad Kunick

Braunschweig University of Technology

View shared research outputs
Top Co-Authors

Avatar

Laurent Meijer

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Maryse Leost

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Connor F. McGrath

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Richard L. Cysyk

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Adrian M. Senderowicz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Tam Luong Nguyen

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge